Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea

Mi Seon Han, Eun Hwa Choi, Sung Hee Chang, Byoung-Lo Jin, Eun Joo Lee, Baek Nam Kim, Min Kyoung Kim, Kihyun Doo, Ju-Hee Seo, Yae-Jean Kim, Yeo Jin Kim, Ji Young Park, Sun Bok Suh, Hyunju Lee, Eun Young Cho, Dong Hyun Kim, Jong Min Kim, Hye Young Kim, Su Eun Park, Joon Kee Lee, Dae Sun Jo, Seung-Man Cho, Jae Hong Choi, Kyo Jin Jo, Young June Choe, Ki Hwan Kim, Jong-Hyun Kim, Mi Seon Han, Eun Hwa Choi, Sung Hee Chang, Byoung-Lo Jin, Eun Joo Lee, Baek Nam Kim, Min Kyoung Kim, Kihyun Doo, Ju-Hee Seo, Yae-Jean Kim, Yeo Jin Kim, Ji Young Park, Sun Bok Suh, Hyunju Lee, Eun Young Cho, Dong Hyun Kim, Jong Min Kim, Hye Young Kim, Su Eun Park, Joon Kee Lee, Dae Sun Jo, Seung-Man Cho, Jae Hong Choi, Kyo Jin Jo, Young June Choe, Ki Hwan Kim, Jong-Hyun Kim

Abstract

Importance: There is limited information describing the full spectrum of coronavirus disease 2019 (COVID-19) and the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection in children.

Objective: To analyze the full clinical course and the duration of SARS-CoV-2 RNA detectability in children confirmed with COVID-19 in the Republic of Korea, where rigorous public health interventions have been implemented.

Design, setting, and participants: This case series of children with COVID-19 was conducted in 20 hospitals and 2 nonhospital isolation facilities across the country from February 18, 2020, to March 31, 2020. Children younger than 19 years who had COVID-19 were included.

Exposures: Confirmed COVID-19, detected via SARS-CoV-2 RNA in a combined nasopharyngeal and oropharyngeal swab or sputum by real-time reverse transcription-polymerase chain reaction.

Main outcomes and measures: Clinical manifestations during the observation period, including the time and duration of symptom occurrence. The duration of SARS-CoV-2 RNA detection was also analyzed.

Results: A total of 91 children with COVID-19 were included (median [range] age, 11 [0-18] years; 53 boys [58%]). Twenty children (22%) were asymptomatic during the entire observation period. Among 71 symptomatic cases, 47 children (66%) had unrecognized symptoms before diagnosis, 18 (25%) developed symptoms after diagnosis, and only 6 (9%) were diagnosed at the time of symptom onset. Twenty-two children (24%) had lower respiratory tract infections. The mean (SD) duration of the presence of SARS-CoV-2 RNA in upper respiratory samples was 17.6 (6.7) days. Virus RNA was detected for a mean (SD) of 14.1 (7.7) days in asymptomatic individuals. There was no difference in the duration of virus RNA detection between children with upper respiratory tract infections and lower respiratory tract infections (mean [SD], 18.7 [5.8] days vs 19.9 [5.6] days; P = .54). Fourteen children (15%) were treated with lopinavir-ritonavir and/or hydroxychloroquine. All recovered, without any fatal cases.

Conclusions and relevance: In this case series study, inapparent infections in children may have been associated with silent COVID-19 transmission in the community. Heightened surveillance using laboratory screening will allow detection in children with unrecognized SARS-CoV-2 infection.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Epidemic Curve of Children With…
Figure 1.. Epidemic Curve of Children With Coronavirus Disease 2019 in Korea From February 14 to March 31, 2020
Other contacts indicates close contact with a kindergarten teacher, care helper at a rehabilitation center, or with other individual with a confirmed case without a social relationship.
Figure 2.. Time Course From Time of…
Figure 2.. Time Course From Time of Diagnosis to End of Isolation in Children With Coronavirus Disease 2019
Time courses are presented according to the spectrum of symptom occurrence. Health care isolation was lifted when patients had improved symptoms and 2 consecutive negative polymerase chain reaction results from nasopharyngeal and oropharyngeal swab specimens collected at least 24 hours apart. The dark colors indicate the symptomatic period, and the light colors indicate the asymptomatic period. The gray dots indicate the date of release from isolation.
Figure 3.. Duration From Symptom Onset to…
Figure 3.. Duration From Symptom Onset to Negative Test Results and End of Isolation
A, The mean duration from symptom onset to negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) results of the asymptomatic group and the groups with upper respiratory tract infection (URTIs) and lower respiratory tract infection (LRTIs). The line indicates the mean value. B, Kaplan-Meier curve for time to end of isolation. Health care isolation was lifted when patients had improved symptoms and 2 consecutive negative polymerase chain reaction results from nasopharyngeal and oropharyngeal swab specimens collected at least 24 hours apart. For asymptomatic cases, the number of days from diagnosis, instead of days from symptom onset, was applied.

References

    1. World Health Organization Coronavirus disease (COVID-19): situation report–91. Published April 20, 2020. Accessed April 22, 2020.
    1. Kim JY, Choe PG, Oh Y, et al. . The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020;35(5):e61. doi:10.3346/jkms.2020.35.e61
    1. Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention . Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112. doi:10.3346/jkms.2020.35.e112
    1. Korea Centers for Disease Control & Prevention COVID-19 response: Korean government’s response system (as of February 25, 2020). Published February 25, 2020. Accessed April 22, 2020.
    1. Korea Centers for Disease Control & Prevention The updates of COVID-19 in the Republic of Korea. Accessed April 20, 2020.
    1. Park JY, Han MS, Park KU, Kim JY, Choi EH. First pediatric case of coronavirus disease 2019 in Korea. J Korean Med Sci. 2020;35(11):e124. doi:10.3346/jkms.2020.35.e124
    1. Lu X, Zhang L, Du H, et al. ; Chinese Pediatric Novel Coronavirus Study Team . SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-1665. doi:10.1056/NEJMc2005073
    1. Dong Y, Mo X, Hu Y, et al. . Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
    1. CDC COVID-19 Response Team Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346. doi:10.15585/mmwr.mm6912e2
    1. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20(6):689-696. doi:10.1016/S1473-3099(20)30198-5
    1. Korea Centers for Disease Control & Prevention COVID-19 guideline. Accessed April 22, 2020.
    1. Yoo SY, Lee Y, Lee GH, Kim DH. Reactivation of SARS-CoV-2 after recovery. Pediatr Int. 2020;62(7):879-881. doi:10.1111/ped.14312
    1. Han MS, Seong MW, Kim N, et al. . Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul. Emerg Infect Dis. 2020;26(10). doi:10.3201/eid2610.202449
    1. Centers for Disease Control and Prevention Overview of testing for SARS-CoV-2. Accessed April 20, 2020.
    1. Castagnoli R, Votto M, Licari A, et al. . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020. doi:10.1001/jamapediatrics.2020.1467
    1. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. . Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261. doi:10.1007/s00405-020-05965-1
    1. Li R, Pei S, Chen B, et al. . Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489-493. doi:10.1126/science.abb3221
    1. Rothe C, Schunk M, Sothmann P, et al. . Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. doi:10.1056/NEJMc2001468
    1. Wang X, Zhang X, He J. Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China. Biosci Trends. 2020;14(1):3-8. doi:10.5582/bst.2020.01043
    1. Carenzo L, Costantini E, Greco M, et al. . Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy. Anaesthesia. 2020;75(7):928-934. doi:10.1111/anae.15072
    1. Xiang YT, Yang Y, Li W, et al. . Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228-229. doi:10.1016/S2215-0366(20)30046-8
    1. Bai Y, Yao L, Wei T, et al. . Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020. doi:10.1001/jama.2020.2565
    1. Li C, Ji F, Wang L, et al. . Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020;26(7):1626-1628. doi:10.3201/eid2607.200718
    1. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2—Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-415. doi:10.15585/mmwr.mm6914e1
    1. He X, Lau EHY, Wu P, et al. . Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-675. doi:10.1038/s41591-020-0869-5

Source: PubMed

3
Abonnere